InSilico Medicine Cayman TopCo (HKG:3696)

HKG:3696 Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022
Revenue	56.24	85.83	51.18	30.15
Revenue Growth (YoY)	-34.48%	67.71%	69.77%	-
Cost of Revenue	10.39	8.26	12.61	11.04
Gross Profit	45.85	77.58	38.57	19.11
Selling, General & Admin	23.74	23.02	25.12	20.82
Research & Development	81.38	91.9	97.34	78.18
Operating Expenses	105.83	114.91	122.3	99.23
Operating Income	-59.99	-37.33	-83.73	-80.12
Interest Expense	-0.21	-0.09	-0.09	-0.1
Interest & Investment Income	5.55	6.53	4.12	0.22
Currency Exchange Gain (Loss)	-0.26	0.47	-0.12	-0.57
Other Non Operating Income (Expenses)	-302.02	8.82	-133.52	-138.08
EBT Excluding Unusual Items	-356.93	-21.61	-213.35	-218.64
Gain (Loss) on Sale of Investments	2.3	0.56	0.45	-1.04
Gain (Loss) on Sale of Assets	-0.13	-	-0.01	-2.19
Other Unusual Items	2.5	4.12	1.35	0.06
Pretax Income	-352.26	-16.94	-211.56	-221.82
Income Tax Expense	0.06	0.16	0.08	0.01
Net Income	-352.32	-17.1	-211.64	-221.83
Net Income to Common	-352.32	-17.1	-211.64	-221.83
Shares Outstanding (Basic)	79	72	68	67
Shares Outstanding (Diluted)	79	72	68	67
Shares Change (YoY)	9.55%	6.33%	0.76%	-
EPS (Basic)	-4.48	-0.24	-3.13	-3.31
EPS (Diluted)	-4.48	-0.24	-3.13	-3.31
Free Cash Flow	-	-58.25	-32.14	-58.5
Free Cash Flow Per Share	-	-0.81	-0.48	-0.87
Gross Margin	81.52%	90.38%	75.36%	63.39%
Operating Margin	-106.66%	-43.49%	-163.60%	-265.75%
Profit Margin	-626.46%	-19.92%	-413.52%	-735.82%
Free Cash Flow Margin	-	-67.86%	-62.79%	-194.03%
EBITDA	-55.52	-32.86	-80.59	-79.43
EBITDA Margin	-98.72%	-38.29%	-157.46%	-263.46%
D&A For EBITDA	4.47	4.47	3.14	0.69
EBIT	-59.99	-37.33	-83.73	-80.12
EBIT Margin	-106.66%	-43.49%	-163.60%	-265.75%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.